Effect of endothelin receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: A systematic review and meta-analysis

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 7, 2015, Pages 1085-1089

  Laban, Kamil G ^a   Vergouwen, Mervyn D I ^a   Dijkhuizen, Rick M ^a   Sena, Emily S ^b   Macleod, Malcolm R ^b   Rinkel, Gabriel J E ^a   Van Der Worp, H Bart ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

animal model; endothelin receptor antagonist; meta analysis; subarachnoid hemorrhage; systematic review

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL; BRAIN CIRCULATION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; META ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

ANIMALS; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 84934442915     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.89     Document Type: Review

References (53)

1. Van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369: 306-318
2. Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 2000; 68: 337-341
3. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998; 50: 876-883
4. Zoerle T, Ilodigwe DC, Wan H, Lakovic K, Sabri M, Ai J, et al. Pharmacologic reduction of angiographic vasospasm in experimental subarachnoid hemorrhage: systematic review and meta-Analysis. J Cereb Blood Flow Metab 2012; 32: 1645-1658
5. Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-Analysis update. Stroke 2012; 43: 2671-2676
6. Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim 2010; 44: 170-175
7. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the preclinical development of drugs for stroke? Trends Neurosci 2007; 30: 433-439
8. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, et al. Metaanalysis of data from animal studies: a practical guide. J Neurosci Methods 2014; 221: 92-102
9. Dersimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. Br Med J 2003; 327: 557-560
11. Light RJ, Pillemer DB. Summing up. The science of reviewing research. Harvard University Press: Cambrige, MA, 1984
12. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634
13. Duval S, Tweedie R. A nonparametric trim and fill method of accounting for publication bias in meta-Analysis. J Am Stat Assoc 2000; 95: 89-98
14. Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, et al. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Brain Res 2011; 1392: 132-139
15. Cirak B, Kiymaz N, Ari HH, Ugras S. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm. Clin Auton Res 2004; 14: 197-201
16. Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 1993; 52: 825-834
17. Cosentino F, McMahon EG, Carter JS, Katusic ZS. Effect of endothelin A-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol 1993; 22: S332-S335
18. Foley PL, Caner HH, Kassell NF, Lee KS. Reversal of subarachnoid hemorrhageinduced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 1994; 34: 108-112
19. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg 1995; 83: 503-509
20. Hirose H, Ide K, Sasaki T, Takahashi R, Kobayashi M, Ikemoto F, et al. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 1995; 277: 77-87
21. Josko J, Hendryk S, Jedrzejowska-Szypulka H, Slowinski J, Gwozdz B, Lange D, et al. Effect of endothelin-1 receptor antagonist BQ-123 on basilar artery diameter after subarachnoid hemorrhage (SAH) in rats. J Physiol Pharmacol 2000; 51: 241-249
22. Kikkawa K, Saito A, Iwasaki H, Ban Y, Yasoshima A, Yamauchi-Kohno R, et al. Prevention of cerebral vasospasm by a novel endothelin receptor antagonist, TA-0201. J Cardiovasc Pharmacol 1999; 34: 666-673
23. Kim CJ, Bassiouny M, Macdonald RL, Weir B, Johns LM. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Stroke 1996; 27: 1629-1633
24. Kita T, Kubo K, Hiramatsu K, Sakaki T, Yonetani Y, Sato S, et al. Profiles of an intravenously available endothelin A-receptor antagonist, S-0139, for preventing cerebral vasospasm in a canine two-hemorrhage model. Life Sci 1998; 63: 305-315
25. Macdonald RL, Johns L, Lin G, Marton LS, Hallak H, Marcoux F, et al. Prevention of vasospasm after subarachnoid hemorrhage in dogs by continuous intravenous infusion of PD156707. Neurol Med Chir 1998; 38: 138-145
26. Nirei H, Hamada K, Shoubo M, Sogabe K, Notsu Y, Ono T. An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci 1993; 52: 1869-1874
27. Pisapia JM, Xu X, Kelly J, Yeung J, Carrion G, Tong H, et al. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cellbound thrombin-Activated pro-urokinase and clazosentan. Exp Neurol 2012; 233: 357-363
28. Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995; 37: 78-85
29. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283: 1110-1118
30. Sabri M, Ai J, Macdonald RL. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 2011; 42: 1454-1460
31. Schubert GA, Schilling L, Thome C. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 2008; 109: 1134-1140
32. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 1995; 37: 87-90
33. Wanebo JE, Louis HG, Arthur AS, Zhou J, Kassell NF, Lee KS, et al. Attenuation of cerebral vasospasm by systemic administration of an endothelin-A receptor antagonist, TBC 11251, in a rabbit model of subarachnoid hemorrhage. Neurosurg Focus 1997; 3: E8
34. Wanebo JE, Arthur AS, Louis HG, West K, Kassell NF, Lee KS, et al. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Neurosurgery 1998; 43: 1409-1417
35. Willette RN, Zhang H, Mitchell MP, Sauermelch CF, Ohlstein EH, Sulpizio AC. Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 1994; 25: 2450-2455
36. Yakubu MA, Leffler CW. Role of endothelin-1 in cerebral hematoma-induced modification of cerebral vascular reactivity in piglets. Brain Res 1996; 734: 149-156
37. Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a bnewly developed orally active endothelin receptor antagonist. Neurosurgery 1996; 38: 115-120
38. Zuccarello M, Lewis AI, Rapoport RM, Endothelin ETA. and ETB receptors in subarachnoid hemorrhage-induced cerebral vasospasm. Eur J Pharmacol 1994; 259: R1-R2
39. Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996; 84: 503-507
40. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998; 29: 1924-1929
41. Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, Manno EM, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 1862-1866
42. Etminan N, Vergouwen MD, Macdonald RL. Angiographic vasospasm versus cerebral infarction as outcome measures after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2013; 115: 33-40
43. Haley EC, Jr, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg 1993; 78: 548-553
44. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; 3: CD000277
45. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med 2010; 7: e1000245
46. Frantzias J, Sena ES, Macleod MR, Al-Shahi Salman R. Treatment of intracerebral hemorrhage in animal models: meta-Analysis. Ann Neurol 2011; 69: 389-399
47. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26: 1465-1478
48. van der Worp HB, de Haan P, Morrema E, Kalkman CJ. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol 2005; 252: 1108-1114
49. Hirst TC, Vesterinen HM, Sena ES, Egan KJ, Macleod MR, Whittle IR. Systematic review and meta-Analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer 2013; 108: 64-71
50. Currie GL, Delaney A, Bennett MI, Dickenson AH, Egan KJ, Vesterinen HM, et al. Animal models of bone cancer pain: systematic review and meta-Analyses. Pain 2013; 154: 917-926
51. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013; 11: e1001609
52. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010; 8: e1000344
53. Dirnagl U, Fisher M. International, multicenter randomized preclinical trials in translational stroke research: it's time to act. J Cereb Blood Flow Metab 2012; 32: 933-935